Loading...

RYTM RHYTHM PHARMACEUTICALS INC Expansion Plans 8-K Filing

RHYT

RYTM

RHYTHM PHARMACEUTICALS INC

(RYTM)

2026 8-K

FDA Approval Update

FDA Approval Announcement

EMANATE Trial Results

Clinical Trial Update

Financial Results Announced

Preliminary Revenue Report

Director Resignation

Phase 2 Trial Results

FDA Application Update

Financial Results

Financial Statements

Product Expansion

Financial Statements

Clinical Trial Results

Agreement Termination

Annual Meeting Notice

Financial Results

Q4 2024 Results

Financial Results

Annual Meeting Results

Financial Results Announcement

Postponement of Annual Meeting

Financial Results Announcement

Entry into a Material Defin...

Investment Agreement

Sales Agreement Amendment

Financial Results Announcement

Regulation FD Disclosure

License Agreement and Share...

Bylaws Amendments

Phase 3 Pediatrics Trial an...

Financial Results Announcement

Sales Agreement with Cowen ...

Departure of Chief Accounti...

Amended Offer Letters for E...

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Deposit Accounts with Silic...

Financial Results Announcement

External Links:

On March 16, 2026, Rhythm Pharmaceuticals reported topline results from its EMANATE trial, showing significant BMI reductions of 9.7% for POMC/PCSK1 Hets and 8.0% for SRC1 after 52 weeks, without new safety concerns.

AI Assistant

RHYTHM PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.